Alterity Therapeutics (ATHE) Total Non-Current Liabilities (2009 - 2026)
Alterity Therapeutics (ATHE) posted Total Non-Current Liabilities of $98096.5 for Q2 2026, up 128.24% on a QoQ basis from $42980.1 in Q4 2025, and up 72.99% year-over-year from $56707.2 in Q2 2025.
Powered by 
Analysis
Alterity Therapeutics (ATHE) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Alterity Therapeutics has reported Total Non-Current Liabilities for 18 years, with the latest figure at $98096.5 in Q2 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 72.99% year-over-year to $98096.5 in Q2 2026; TTM through Jun 2026 was $98096.5, a 72.99% increase from a year earlier, with the FY2026 full-year figure at $98096.5, up 7003.34% from the prior year.
- Total Non-Current Liabilities was $98096.5 for Q2 2026 at Alterity Therapeutics, up from $42980.1 in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $98096.5 in Q2 2026, with the low at $519.14 in Q2 2024.
- Average Total Non-Current Liabilities over 5 years is $40151.6, with a median of $42980.1 recorded in 2025.
- The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities plunged 97.67% in 2023, then surged 10823.29% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $31108.7 in 2022, then jumped by 60.1% to $49804.0 in 2023, then plunged by 43.38% to $28197.3 in 2024, then surged by 52.43% to $42980.1 in 2025, then surged by 128.24% to $98096.5 in 2026.
- The last three Total Non-Current Liabilities figures came in at $98096.5 (Q2 2026), $42980.1 (Q4 2025), and $56707.2 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 378.37 Mn |
| 10 | Alterity Therapeutics | 72.80 Mn | 72.80 Mn | - | 98,096.47 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 98,096.47 |
| Dec 31, 2025 | 42,980.09 |
| Jun 30, 2025 | 56,707.16 |
| Dec 31, 2024 | 28,197.30 |
| Jun 30, 2024 | 519.14 |
| Dec 31, 2023 | 49,804.03 |
| Jun 30, 2023 | 1,227.10 |
| Dec 31, 2022 | 31,108.67 |
| Jun 30, 2022 | 52,724.51 |
| Dec 31, 2021 | 28,873.40 |
| Jun 30, 2021 | 36,709.30 |
| Dec 31, 2020 | 5,912.53 |
| Jun 30, 2020 | 27,778.04 |
| Dec 31, 2019 | 32,731.58 |
| Jun 30, 2019 | 24,499.72 |
| Dec 31, 2018 | 932.62 Mn |
| Jun 30, 2018 | 693.45 Mn |
| Dec 31, 2017 | 480.65 |
| Jun 30, 2017 | 300.48 Mn |
| Dec 31, 2016 | 347.32 |